Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 223

1.

IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia.

Scheffold A, Jebaraj BMC, Tausch E, Bloehdorn J, Ghia P, Yahiaoui A, Dolnik A, Blätte TJ, Bullinger L, Dheenadayalan RP, Li L, Schneider C, Chen SS, Chiorazzi N, Dietrich S, Seiffert M, Tannheimer S, Döhner H, Mertens D, Stilgenbauer S.

Blood. 2019 Apr 22. pii: blood.2018881029. doi: 10.1182/blood.2018881029. [Epub ahead of print]

PMID:
31010847
2.

Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia.

Tausch E, Close W, Dolnik A, Bloehdorn J, Chyla B, Bullinger L, Döhner H, Mertens D, Stilgenbauer S.

Haematologica. 2019 Apr 19. pii: haematol.2019.222588. doi: 10.3324/haematol.2019.222588. [Epub ahead of print]

3.

Retroperitoneal Hematoma after Bone Marrow Biopsy: The First Cut Should Not Be the Deepest.

Wojciechowski A, Duckert M, Hartmann J, Bullinger L, Matzdorff A.

Oncol Res Treat. 2019 Apr 17;42(5):279-284. doi: 10.1159/000499743. [Epub ahead of print]

PMID:
30995669
4.

Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML.

Basheer F, Giotopoulos G, Meduri E, Yun H, Mazan M, Sasca D, Gallipoli P, Marando L, Gozdecka M, Asby R, Sheppard O, Dudek M, Bullinger L, Döhner H, Dillon R, Freeman S, Ottmann O, Burnett A, Russell N, Papaemmanuil E, Hills R, Campbell P, Vassiliou GS, Huntly BJP.

J Exp Med. 2019 Apr 1;216(4):966-981. doi: 10.1084/jem.20181276. Epub 2019 Mar 19.

5.

Neural cell adhesion molecule 1 (NCAM1; CD56) promotes leukemogenesis and confers drug resistance in AML.

Sasca D, Szybinski J, Schüler A, Shah V, Heidelberger J, Haehnel PS, Dolnik A, Kriege O, Fehr EM, Gebhardt WH, Reid G, Scholl C, Theobald M, Bullinger L, Beli P, Kindler T.

Blood. 2019 Feb 27. pii: blood-2018-12-889725. doi: 10.1182/blood-2018-12-889725. [Epub ahead of print]

PMID:
30814062
6.

Analysis of the CDK4/6 Cell Cycle Pathway in Leiomyosarcomas as a Potential Target for Inhibition by Palbociclib.

Böhm MJ, Marienfeld R, Jäger D, Mellert K, von Witzleben A, Brüderlein S, Wittau M, von Baer A, Schultheiss M, Mayer-Steinacker R, Rücker FG, Möller P, Bullinger L, Barth TFE.

Sarcoma. 2019 Jan 21;2019:3914232. doi: 10.1155/2019/3914232. eCollection 2019.

7.

Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial.

Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O, Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F, Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M, Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M; Neurooncology Working Group of the German Cancer Society.

Lancet. 2019 Feb 16;393(10172):678-688. doi: 10.1016/S0140-6736(18)31791-4. Epub 2019 Feb 14.

PMID:
30782343
8.

IDH2 inhibition: another piece to the puzzle.

Bullinger L.

Blood. 2019 Feb 14;133(7):625-626. doi: 10.1182/blood-2018-12-891481. No abstract available.

PMID:
30765493
9.

Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations.

Jutzi JS, Basu T, Pellmann M, Kaiser S, Steinemann D, Sanders MA, Hinai ASA, Zeilemaker A, Bojtine Kovacs S, Koellerer C, Ostendorp J, Aumann K, Wang W, Raffoux E, Cassinat B, Bullinger L, Schlegelberger B, Valk PJM, Pahl HL.

Blood. 2019 Apr 18;133(16):1766-1777. doi: 10.1182/blood-2018-09-875047. Epub 2019 Feb 12.

PMID:
30755419
10.

Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients.

Christen F, Hoyer K, Yoshida K, Hou HA, Waldhueter N, Heuser M, Hills RK, Chan W, Hablesreiter R, Blau O, Ochi Y, Klement P, Chou WC, Blau IW, Tang JL, Zemojtel T, Shiraishi Y, Shiozawa Y, Thol F, Ganser A, Löwenberg B, Linch DC, Bullinger L, Valk PJM, Tien HF, Gale RE, Ogawa S, Damm F.

Blood. 2019 Mar 7;133(10):1140-1151. doi: 10.1182/blood-2018-05-852822. Epub 2019 Jan 4.

PMID:
30610028
11.

Prescription Contraceptive Sales Following the Affordable Care Act.

Bullinger LR, Simon K.

Matern Child Health J. 2019 May;23(5):657-666. doi: 10.1007/s10995-018-2680-1.

PMID:
30600517
12.

Aneuploid acute myeloid leukemia exhibits a signature of genomic alterations in the cell cycle and protein degradation machinery.

Simonetti G, Padella A, do Valle IF, Fontana MC, Fonzi E, Bruno S, Baldazzi C, Guadagnuolo V, Manfrini M, Ferrari A, Paolini S, Papayannidis C, Marconi G, Franchini E, Zuffa E, Laginestra MA, Zanotti F, Astolfi A, Iacobucci I, Bernardi S, Sazzini M, Ficarra E, Hernandez JM, Vandenberghe P, Cools J, Bullinger L, Ottaviani E, Testoni N, Cavo M, Haferlach T, Castellani G, Remondini D, Martinelli G.

Cancer. 2019 Mar 1;125(5):712-725. doi: 10.1002/cncr.31837. Epub 2018 Nov 27.

PMID:
30480765
13.

Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation.

Frick M, Chan W, Arends CM, Hablesreiter R, Halik A, Heuser M, Michonneau D, Blau O, Hoyer K, Christen F, Galan-Sousa J, Noerenberg D, Wais V, Stadler M, Yoshida K, Schetelig J, Schuler E, Thol F, Clappier E, Christopeit M, Ayuk F, Bornhäuser M, Blau IW, Ogawa S, Zemojtel T, Gerbitz A, Wagner EM, Spriewald BM, Schrezenmeier H, Kuchenbauer F, Kobbe G, Wiesneth M, Koldehoff M, Socié G, Kroeger N, Bullinger L, Thiede C, Damm F.

J Clin Oncol. 2019 Feb 10;37(5):375-385. doi: 10.1200/JCO.2018.79.2184. Epub 2018 Nov 7.

PMID:
30403573
14.

Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation.

Jacquelin S, Straube J, Cooper L, Vu T, Song A, Bywater M, Baxter E, Heidecker M, Wackrow B, Porter A, Ling V, Green J, Austin R, Kazakoff S, Waddell N, Hesson LB, Pimanda JE, Stegelmann F, Bullinger L, Döhner K, Rampal RK, Heckl D, Hill GR, Lane SW.

Blood. 2018 Dec 27;132(26):2707-2721. doi: 10.1182/blood-2018-04-846220. Epub 2018 Oct 26.

PMID:
30366920
15.

Nuclear FOXO1 promotes lymphomagenesis in germinal center B cells.

Kabrani E, Chu VT, Tasouri E, Sommermann T, Baßler K, Ulas T, Zenz T, Bullinger L, Schultze JL, Rajewsky K, Sander S.

Blood. 2018 Dec 20;132(25):2670-2683. doi: 10.1182/blood-2018-06-856203. Epub 2018 Oct 17.

PMID:
30333121
16.

Cytogenetics and gene mutations influence survival in older patients with acute myeloid leukemia treated with azacitidine or conventional care.

Döhner H, Dolnik A, Tang L, Seymour JF, Minden MD, Stone RM, Del Castillo TB, Al-Ali HK, Santini V, Vyas P, Beach CL, MacBeth KJ, Skikne BS, Songer S, Tu N, Bullinger L, Dombret H.

Leukemia. 2018 Dec;32(12):2546-2557. doi: 10.1038/s41375-018-0257-z. Epub 2018 Oct 1.

17.

Circular RNAs in Cancer.

Lux S, Bullinger L.

Adv Exp Med Biol. 2018;1087:215-230. doi: 10.1007/978-981-13-1426-1_17. Review.

PMID:
30259369
18.

The Affordable Care Act, Breastfeeding, and Breast Pump Health Insurance Coverage.

Kapinos KA, Bullinger L, Gurley-Calvez T.

JAMA Pediatr. 2018 Nov 1;172(11):1002-1004. doi: 10.1001/jamapediatrics.2018.2003. No abstract available.

PMID:
30208472
19.

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.

Thol F, Gabdoulline R, Liebich A, Klement P, Schiller J, Kandziora C, Hambach L, Stadler M, Koenecke C, Flintrop M, Pankratz M, Wichmann M, Neziri B, Büttner K, Heida B, Klesse S, Chaturvedi A, Kloos A, Göhring G, Schlegelberger B, Gaidzik VI, Bullinger L, Fiedler W, Heim A, Hamwi I, Eder M, Krauter J, Schlenk RF, Paschka P, Döhner K, Döhner H, Ganser A, Heuser M.

Blood. 2018 Oct 18;132(16):1703-1713. doi: 10.1182/blood-2018-02-829911. Epub 2018 Sep 6.

PMID:
30190321
20.

Author Correction: BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation.

Raffel S, Falcone M, Kneisel N, Hansson J, Wang W, Lutz C, Bullinger L, Poschet G, Nonnenmacher Y, Barnert A, Bahr C, Zeisberger P, Przybylla A, Sohn M, Tönjes M, Erez A, Adler L, Jensen P, Scholl C, Fröhling S, Cocciardi S, Wuchter P, Thiede C, Flörcken A, Westermann J, Ehninger G, Lichter P, Hiller K, Hell R, Herrmann C, Ho AD, Krijgsveld J, Radlwimmer B, Trumpp A.

Nature. 2018 Aug;560(7718):E28. doi: 10.1038/s41586-018-0403-9.

PMID:
30069041
21.

Correction: MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences.

L'Abbate A, Tolomeo D, Cifola I, Severgnini M, Turchiano A, Augello B, Squeo G, D'Addabbo P, Traversa D, Daniele G, Lonoce A, Pafundi M, Carella M, Palumbo O, Dolnik A, Muehlematter D, Schoumans J, Van Roy N, De Bellis G, Martinelli G, Merla G, Bullinger L, Haferlach C, Storlazzi CT.

Leukemia. 2018 Oct;32(10):2304. doi: 10.1038/s41375-018-0177-y.

PMID:
29985446
22.

MYB induces the expression of the oncogenic corepressor SKI in acute myeloid leukemia.

Frech M, Teichler S, Feld C, Bouchard C, Berberich H, Sorg K, Mernberger M, Bullinger L, Bauer UM, Neubauer A.

Oncotarget. 2018 Apr 27;9(32):22423-22435. doi: 10.18632/oncotarget.25051. eCollection 2018 Apr 27.

23.

Tyrosine kinase inhibitor-induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors.

Maifrede S, Nieborowska-Skorska M, Sullivan-Reed K, Dasgupta Y, Podszywalow-Bartnicka P, Le BV, Solecka M, Lian Z, Belyaeva EA, Nersesyan A, Machnicki MM, Toma M, Chatain N, Rydzanicz M, Zhao H, Jelinek J, Piwocka K, Sliwinski T, Stoklosa T, Ploski R, Fischer T, Sykes SM, Koschmieder S, Bullinger L, Valent P, Wasik MA, Huang J, Skorski T.

Blood. 2018 Jul 5;132(1):67-77. doi: 10.1182/blood-2018-02-834895. Epub 2018 May 21.

PMID:
29784639
24.

UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs.

Gozdecka M, Meduri E, Mazan M, Tzelepis K, Dudek M, Knights AJ, Pardo M, Yu L, Choudhary JS, Metzakopian E, Iyer V, Yun H, Park N, Varela I, Bautista R, Collord G, Dovey O, Garyfallos DA, De Braekeleer E, Kondo S, Cooper J, Göttgens B, Bullinger L, Northcott PA, Adams D, Vassiliou GS, Huntly BJP.

Nat Genet. 2018 Jun;50(6):883-894. doi: 10.1038/s41588-018-0114-z. Epub 2018 May 7.

25.

Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial.

Paschka P, Schlenk RF, Weber D, Benner A, Bullinger L, Heuser M, Gaidzik VI, Thol F, Agrawal M, Teleanu V, Lübbert M, Fiedler W, Radsak M, Krauter J, Horst HA, Greil R, Mayer K, Kündgen A, Martens U, Heil G, Salih HR, Hertenstein B, Schwänen C, Wulf G, Lange E, Pfreundschuh M, Ringhoffer M, Girschikofsky M, Heinicke T, Kraemer D, Göhring G, Ganser A, Döhner K, Döhner H.

Leukemia. 2018 Jul;32(7):1621-1630. doi: 10.1038/s41375-018-0129-6. Epub 2018 Apr 17.

PMID:
29720733
26.

RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia.

Rudat S, Pfaus A, Cheng YY, Holtmann J, Ellegast JM, Bühler C, Marcantonio DD, Martinez E, Göllner S, Wickenhauser C, Müller-Tidow C, Lutz C, Bullinger L, Milsom MD, Sykes SM, Fröhling S, Scholl C.

Leukemia. 2018 Oct;32(10):2189-2202. doi: 10.1038/s41375-018-0102-4. Epub 2018 Mar 22.

PMID:
29654265
27.

Epigenetic therapy: azacytidine and decitabine in acute myeloid leukemia.

Bohl SR, Bullinger L, Rücker FG.

Expert Rev Hematol. 2018 May;11(5):361-371. doi: 10.1080/17474086.2018.1453802. Epub 2018 Mar 27. Review.

PMID:
29543073
28.

FACS single cell index sorting is highly reliable and determines immune phenotypes of clonally expanded T cells.

Penter L, Dietze K, Bullinger L, Westermann J, Rahn HP, Hansmann L.

Eur J Immunol. 2018 Jul;48(7):1248-1250. doi: 10.1002/eji.201847507. Epub 2018 Apr 3.

PMID:
29537492
29.

Hematopoietic lineage distribution and evolutionary dynamics of clonal hematopoiesis.

Arends CM, Galan-Sousa J, Hoyer K, Chan W, Jäger M, Yoshida K, Seemann R, Noerenberg D, Waldhueter N, Fleischer-Notter H, Christen F, Schmitt CA, Dörken B, Pelzer U, Sinn M, Zemojtel T, Ogawa S, Märdian S, Schreiber A, Kunitz A, Krüger U, Bullinger L, Mylonas E, Frick M, Damm F.

Leukemia. 2018 Sep;32(9):1908-1919. doi: 10.1038/s41375-018-0047-7. Epub 2018 Mar 1.

PMID:
29491455
30.

MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences.

L Abbate A, Tolomeo D, Cifola I, Severgnini M, Turchiano A, Augello B, Squeo G, D Addabbo P, Traversa D, Daniele G, Lonoce A, Pafundi M, Carella M, Palumbo O, Dolnik A, Muehlematter D, Schoumans J, Van Roy N, De Bellis G, Martinelli G, Merla G, Bullinger L, Haferlach C, Storlazzi CT.

Leukemia. 2018 Oct;32(10):2152-2166. doi: 10.1038/s41375-018-0033-0. Epub 2018 Feb 22. Erratum in: Leukemia. 2018 Jul 9;:.

31.

The cell fate determinant Scribble is required for maintenance of hematopoietic stem cell function.

Mohr J, Dash BP, Schnoeder TM, Wolleschak D, Herzog C, Tubio Santamaria N, Weinert S, Godavarthy S, Zanetti C, Naumann M, Hartleben B, Huber TB, Krause DS, Kähne T, Bullinger L, Heidel FH.

Leukemia. 2018 May;32(5):1211-1221. doi: 10.1038/s41375-018-0025-0. Epub 2018 Jan 30.

PMID:
29467485
32.

Bevacizumab in temozolomide refractory high-grade gliomas: single-centre experience and review of the literature.

Jeck J, Kassubek R, Coburger J, Edenhofer S, Schönsteiner SS, Ludolph AC, Schmitz B, Engelke J, Mayer-Steinacker R, Lewerenz J, Bullinger L.

Ther Adv Neurol Disord. 2018 Jan 21;11:1756285617753597. doi: 10.1177/1756285617753597. eCollection 2018.

33.

Effect of the Affordable Care Act on Breastfeeding Outcomes.

Gurley-Calvez T, Bullinger L, Kapinos KA.

Am J Public Health. 2018 Feb;108(2):277-283. doi: 10.2105/AJPH.2017.304108. Epub 2017 Dec 21.

PMID:
29267066
34.

Expression of CD274 (PD-L1) is associated with unfavourable recurrent mutations in AML.

Zajac M, Zaleska J, Dolnik A, Bullinger L, Giannopoulos K.

Br J Haematol. 2018 Dec;183(5):822-825. doi: 10.1111/bjh.15040. Epub 2017 Dec 19. No abstract available.

PMID:
29265177
35.

Analysis of NPM1 splice variants reveals differential expression patterns of prognostic value in acute myeloid leukemia.

Zajac M, Dolnik A, Stasiak G, Zaleska J, Kielbus M, Czapinski J, Schunn M, Correa SC, Glodkowska-Mrowka E, Sundaram RC, Jankowska-Lecka O, Schlenk RF, Döhner H, Döhner K, Stepulak A, Bullinger L, Giannopoulos K.

Oncotarget. 2017 Aug 3;8(56):95163-95175. doi: 10.18632/oncotarget.19871. eCollection 2017 Nov 10.

36.

Protein phosphatase 4 regulatory subunit 2 (PPP4R2) is recurrently deleted in acute myeloid leukemia and required for efficient DNA double strand break repair.

Herzig JK, Bullinger L, Tasdogan A, Zimmermann P, Schlegel M, Teleanu V, Weber D, Rücker FG, Paschka P, Dolnik A, Schneider E, Kuchenbauer F, Heidel FH, Buske C, Döhner H, Döhner K, Gaidzik VI.

Oncotarget. 2017 Sep 21;8(56):95038-95053. doi: 10.18632/oncotarget.21119. eCollection 2017 Nov 10.

37.

Micro-ribonucleic acid-155 is a direct target of Meis1, but not a driver in acute myeloid leukemia.

Schneider E, Staffas A, Röhner L, Malmberg ED, Ashouri A, Krowiorz K, Pochert N, Miller C, Wei SY, Arabanian L, Buske C, Döhner H, Bullinger L, Fogelstrand L, Heuser M, Döhner K, Xiang P, Ruschmann J, Petriv OI, Heravi-Moussavi A, Hansen CL, Hirst M, Humphries RK, Rouhi A, Palmqvist L, Kuchenbauer F.

Haematologica. 2018 Feb;103(2):246-255. doi: 10.3324/haematol.2017.177485. Epub 2017 Dec 7.

38.

MYC-containing amplicons in acute myeloid leukemia: Genomic structures, evolution, and transcriptional consequences.

ĹAbbate A, Tolomeo D, Cifola I, Severgnini M, Turchiano A, Augello B, Squeo G, D Addabbo P, Traversa D, Daniele G, Lonoce A, Pafundi M, Carella M, Palumbo O, Dolnik A, Muehlematter D, Schoumans J, Van Roy N, De Bellis G, Martinelli G, Merla G, Bullinger L, Haferlach C, Storlazzi CT.

Leukemia. 2017 Nov 28. doi: 10.1038/leu.2017.337. [Epub ahead of print]

PMID:
29180669
39.

BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation.

Raffel S, Falcone M, Kneisel N, Hansson J, Wang W, Lutz C, Bullinger L, Poschet G, Nonnenmacher Y, Barnert A, Bahr C, Zeisberger P, Przybylla A, Sohn M, Tönjes M, Erez A, Adler L, Jensen P, Scholl C, Fröhling S, Cocciardi S, Wuchter P, Thiede C, Flörcken A, Westermann J, Ehninger G, Lichter P, Hiller K, Hell R, Herrmann C, Ho AD, Krijgsveld J, Radlwimmer B, Trumpp A.

Nature. 2017 Nov 16;551(7680):384-388. doi: 10.1038/nature24294. Epub 2017 Nov 8. Erratum in: Nature. 2018 Aug;560(7718):E28.

PMID:
29144447
40.

Reduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome.

Wais V, Kündgen L, Bohl SR, von Harsdorf S, Schlenk RF, Döhner K, Teleanu V, Bullinger L, Nguyen TM, Drognitz K, Moulin JC, Binnenhei M, Bentz M, Döhner H, Bunjes D, Kuchenbauer F, Ringhoffer M.

Bone Marrow Transplant. 2018 Jan;53(1):94-96. doi: 10.1038/bmt.2017.211. Epub 2017 Nov 13. No abstract available.

PMID:
29131153
41.

Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO).

Nagel G, Weber D, Fromm E, Erhardt S, Lübbert M, Fiedler W, Kindler T, Krauter J, Brossart P, Kündgen A, Salih HR, Westermann J, Wulf G, Hertenstein B, Wattad M, Götze K, Kraemer D, Heinicke T, Girschikofsky M, Derigs HG, Horst HA, Rudolph C, Heuser M, Göhring G, Teleanu V, Bullinger L, Thol F, Gaidzik VI, Paschka P, Döhner K, Ganser A, Döhner H, Schlenk RF; German-Austrian AML Study Group (AMLSG).

Ann Hematol. 2017 Dec;96(12):1993-2003. doi: 10.1007/s00277-017-3150-3. Epub 2017 Oct 31.

42.

Chromothripsis is linked to TP53 alteration, cell cycle impairment, and dismal outcome in acute myeloid leukemia with complex karyotype.

Rücker FG, Dolnik A, Blätte TJ, Teleanu V, Ernst A, Thol F, Heuser M, Ganser A, Döhner H, Döhner K, Bullinger L.

Haematologica. 2018 Jan;103(1):e17-e20. doi: 10.3324/haematol.2017.180497. Epub 2017 Oct 27. No abstract available.

43.

Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia.

Hirsch S, Blätte TJ, Grasedieck S, Cocciardi S, Rouhi A, Jongen-Lavrencic M, Paschka P, Krönke J, Gaidzik VI, Döhner H, Schlenk RF, Kuchenbauer F, Döhner K, Dolnik A, Bullinger L.

Haematologica. 2017 Dec;102(12):2039-2047. doi: 10.3324/haematol.2017.172866. Epub 2017 Sep 29.

44.

Acute myeloid leukemia with mutated nucleophosmin 1: an immunogenic acute myeloid leukemia subtype and potential candidate for immune checkpoint inhibition.

Greiner J, Hofmann S, Schmitt M, Götz M, Wiesneth M, Schrezenmeier H, Bunjes D, Döhner H, Bullinger L.

Haematologica. 2017 Dec;102(12):e499-e501. doi: 10.3324/haematol.2017.176461. Epub 2017 Sep 21. No abstract available.

45.

The oligodendrocyte lineage transcription factor 2 (OLIG2) is epigenetically regulated in acute myeloid leukemia.

Yalcin A, Kovarbasic M, Wehrle J, Claus R, Becker H, Abdelkarim M, Gaidzik VI, Schmidts A, Wäsch R, Pahl HL, Döhner K, Bullinger L, Duyster J, Lübbert M, Hackanson B.

Exp Hematol. 2017 Nov;55:76-85.e3. doi: 10.1016/j.exphem.2017.07.009. Epub 2017 Jul 28.

PMID:
28760688
46.

Partitioned learning of deep Boltzmann machines for SNP data.

Hess M, Lenz S, Blätte TJ, Bullinger L, Binder H.

Bioinformatics. 2017 Oct 15;33(20):3173-3180. doi: 10.1093/bioinformatics/btx408.

PMID:
28655145
47.

DNMT3A mutant transcript levels persist in remission and do not predict outcome in patients with acute myeloid leukemia.

Gaidzik VI, Weber D, Paschka P, Kaumanns A, Krieger S, Corbacioglu A, Krönke J, Kapp-Schwoerer S, Krämer D, Horst HA, Schmidt-Wolf I, Held G, Kündgen A, Ringhoffer M, Götze K, Kindler T, Fiedler W, Wattad M, Schlenk RF, Bullinger L, Teleanu V, Schlegelberger B, Thol F, Heuser M, Ganser A, Döhner H, Döhner K; German-Austrian Acute Myeloid Leukemia Study Group (AMLSG).

Leukemia. 2018 Jan;32(1):30-37. doi: 10.1038/leu.2017.200. Epub 2017 Jun 23.

PMID:
28643785
48.

Novel Treatment Options in Head and Neck Cancer.

Schuler PJ, Laban S, Doescher J, Bullinger L, Hoffmann TK.

Oncol Res Treat. 2017;40(6):342-346. doi: 10.1159/000477254. Epub 2017 May 17. Review.

49.

Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells.

Nieborowska-Skorska M, Sullivan K, Dasgupta Y, Podszywalow-Bartnicka P, Hoser G, Maifrede S, Martinez E, Di Marcantonio D, Bolton-Gillespie E, Cramer-Morales K, Lee J, Li M, Slupianek A, Gritsyuk D, Cerny-Reiterer S, Seferynska I, Stoklosa T, Bullinger L, Zhao H, Gorbunova V, Piwocka K, Valent P, Civin CI, Muschen M, Dick JE, Wang JC, Bhatia S, Bhatia R, Eppert K, Minden MD, Sykes SM, Skorski T.

J Clin Invest. 2017 Jun 1;127(6):2392-2406. doi: 10.1172/JCI90825. Epub 2017 May 8.

50.

Heterodimerization of AML1/ETO with CBFβ is required for leukemogenesis but not for myeloproliferation.

Thiel VN, Giaimo BD, Schwarz P, Soller K, Vas V, Bartkuhn M, Blätte TJ, Döhner K, Bullinger L, Borggrefe T, Geiger H, Oswald F.

Leukemia. 2017 Nov;31(11):2491-2502. doi: 10.1038/leu.2017.105. Epub 2017 Mar 31.

Supplemental Content

Loading ...
Support Center